Literature DB >> 31313405

The ameliorating effects of Bushen Tiaoxue Granules and Kunling Wan on impaired angiogenesis and endometrial receptivity in rats following controlled ovarian hyperstimulation.

Bo-Yang Lv1, Hao-Yu Sun2, Quan Li3,4,5,6,7, Hao-Lin Zhang1, Chun-Shui Pan3,4,5,6,7, Li Yan3,4,5,6,7, Jing-Yu Fan3,4,5,6,7, Dong Li1, Jing-Yan Han2,3,4,5,6,7.   

Abstract

OBJECTIVE: To investigate the effects of Bushen Tiaoxue Granules and Kunling Wan, the two Chinese medicines, on vascular dysfunction and the impairment of endometrial receptivity caused by controlled ovarian hyperstimulation and its underlying mechanism.
METHODS: Female Sprague Dawley rats with regular estrous cycle were enrolled and given Bushen Tiaoxue Granules or Kunling Wan by gavage for 12 days, and then, controlled ovarian hyperstimulation model was induced. We assessed endometrial microvessels, endometrial blood flow, levels of estradiol and progesterone in serum, vascular endothelial growth factor A upstream molecules estrogen and progesterone receptors in the endometrium, and pregnancy outcome.
RESULTS: Pre-treatment of Bushen Tiaoxue Granules or Kunling Wan increases endometrial blood flow of controlled ovarian hyperstimulation rats, up-regulates vascular endothelial growth factor A and microvessels, improves the endometrial morphology of controlled ovarian hyperstimulation rats during implantation, decreases the super physiological concentration of estradiol and progesterone in serum, and increases the expression of vascular endothelial growth factor A upstream molecules estrogen and progesterone receptors in the endometrium. In addition, Bushen Tiaoxue Granules or Kunling Wan elevates the lysophosphatidic acid receptor 3 that participates in vascularization and increases the expression of leukemia inhibitory factor through up-regulating the expression of p53 in the endometrium, ultimately affecting pregnancy outcome.
CONCLUSION: This study demonstrated Bushen Tiaoxue Granules or Kunling Wan as a potential strategy for prevention of impairment in angiogenesis and endometrial receptivity induced by controlled ovarian hyperstimulation.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  Bushen Tiaoxue Granules; Kunling Wan; angiogenesis; controlled ovarian hyperstimulation; vascular dysfunction

Mesh:

Substances:

Year:  2019        PMID: 31313405     DOI: 10.1111/micc.12581

Source DB:  PubMed          Journal:  Microcirculation        ISSN: 1073-9688            Impact factor:   2.628


  5 in total

1.  Proteomic Analysis of Human Follicular Fluid Reveals the Pharmacological Mechanisms of the Chinese Patent Drug Kunling Pill for Improving Diminished Ovarian Reserve.

Authors:  Haiyan Wang; Dan Cao; Meixian Wang; Yanbin Shi; Bowen Wei; Shiyuan Jiang; Yangyu Jiang; Hui Lian; Xiaoou Xue; Zhiqiang Ma; Jian Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-28       Impact factor: 2.650

2.  Bushen Huoxue recipe attenuates early pregnancy loss via activating endometrial COX2-PGE2 angiogenic signaling in mice.

Authors:  Yufan Song; Fanru Zhou; Xiujuan Tan; Xia Liu; Jiahui Ding; Chu Zhang; Fan Li; Wenxin Zhu; Wenwen Ma; Runan Hu; Mingmin Zhang
Journal:  BMC Complement Med Ther       Date:  2021-01-14

3.  The Ameliorating Effects of Bushen Huatan Granules and Kunling Wan on Polycystic Ovary Syndrome Induced by Dehydroepiandrosterone in Rats.

Authors:  Yang Xu; Chun-Shui Pan; Quan Li; Hao-Lin Zhang; Li Yan; Gulinigaer Anwaier; Xiao-Yi Wang; Lu-Lu Yan; Jing-Yu Fan; Dong Li; Jing-Yan Han
Journal:  Front Physiol       Date:  2021-03-08       Impact factor: 4.566

Review 4.  The Treatment of Complementary and Alternative Medicine on Female Infertility Caused by Endometrial Factors.

Authors:  Jing Lin; Haoyue Ma; Hang Li; Jing Han; Tingting Guo; Zhen Qin; Liyan Jia; Yuehui Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-07       Impact factor: 2.650

Review 5.  Autophagy as a Therapeutic Target of Natural Products Enhancing Embryo Implantation.

Authors:  Hyerin Park; Minkyoung Cho; Yoonju Do; Jang-Kyung Park; Sung-Jin Bae; Jongkil Joo; Ki-Tae Ha
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.